Insight Wealth Strategies LLC Purchases New Shares in Illumina, Inc. $ILMN

Insight Wealth Strategies LLC bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 32,967 shares of the life sciences company’s stock, valued at approximately $6,062,000.

A number of other institutional investors also recently modified their holdings of the business. Empowered Funds LLC grew its position in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Illumina in the second quarter valued at approximately $621,000. CW Advisors LLC bought a new stake in shares of Illumina in the second quarter valued at approximately $275,000. Marshall Wace LLP grew its position in Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after buying an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC grew its position in Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after buying an additional 1,748 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Citigroup raised their price target on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Deutsche Bank Aktiengesellschaft lowered Illumina to a “hold” rating in a research note on Wednesday, August 5th. Stifel Nicolaus increased their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $188.40.

Insider Buying and Selling

In other news, CAO Scott D. Ericksen sold 500 shares of the stock in a transaction on Friday, May 29th. The shares were sold at an average price of $160.00, for a total value of $80,000.00. Following the transaction, the chief accounting officer owned 14,446 shares of the company’s stock, valued at $2,311,360. This represents a 3.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $200.00, for a total value of $123,000.00. Following the sale, the insider owned 20,338 shares in the company, valued at $4,067,600. The trade was a 2.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,519,744 shares of company stock valued at $271,138,789. 2.90% of the stock is owned by company insiders.

Illumina Stock Performance

Shares of ILMN stock opened at $192.84 on Wednesday. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $207.00. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm has a fifty day simple moving average of $182.28 and a two-hundred day simple moving average of $149.70. The firm has a market capitalization of $29.12 billion, a PE ratio of 35.98, a price-to-earnings-growth ratio of 2.70 and a beta of 1.44.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.